Implication of cardiac remodeling in heart failure: Mechanisms and therapeutic strategies

Internal Medicine

Volumn 42, Issue 6, 2003, Pages 465-469

  Takano, Hiroyuki ^a   Hasegawa, Hiroshi ^a   Nagai, Toshio ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Extracellular matrix; Matrix metalloproteinase; Myocardial infarction; Regeneration; blacker

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENZYME; FLUINDOSTATIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ION CHANNEL; LOSARTAN; METOPROLOL; NEUROHORMONE; PLACEBO; RAMIPRIL; SCLEROPROTEIN; TRANDOLAPRIL; VALSARTAN;

ADAPTATION; CARDIOVASCULAR DISEASE; CELL TRANSPLANTATION; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY BLOOD VESSEL; DISEASE ASSOCIATION; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROBLAST; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HEMATOPOIETIC STEM CELL; HUMAN; MECHANICAL STRESS; MYOCARDITIS; NONHUMAN; PATHOGENESIS; REVIEW; TISSUE REGENERATION; VALVULAR HEART DISEASE;

EID: 0042171678     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.465     Document Type: Review

References (32)

1. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 100: 999-1008, 1999.
2. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 35: 569-582, 2000.
3. Yang Z, Bove CM, French BA, et al. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 106: 106-111, 2002.
4. Delcayre C, Silvestre JS, Garnier A, et al. Cardiac aldosterone production and ventricular remodeling. Kidney Int 57: 1346-1351, 2000.
5. Duchman SM, Thohan V, Kalra D, Toffe-Amione G. Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure. Curr Opin Cardiol 15: 136-140, 2000.
6. Singh K, Xiao L, Remondino A, Sawyer DB, Colucci WS. Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol 189: 257-265, 2001.
7. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res 53: 822-830, 2002.
8. Li YY, Feng YQ, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 97: 12746-12751, 2000.
9. Gurantz D, Cowling RT, Villarreal FJ, Greenberg BH. Tumor necrosis factor-alpha upregulates angiotensin II type 1 receptors on cardiac fibroblasts. Circ Res 85: 272-279, 1999.
10. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-beta 1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109: 787-796, 2002.
11. van Wamel AJ, Ruwhof C, van der Valk-Kokshoom LE, Schrier PI, van der Laarse A. The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol Cell Biochem 218: 113-124, 2001.
12. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90: 520-530, 2002.
13. Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 106: 857-866, 2000.
14. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106: 55-62, 2000.
15. Roten L, Nemoto S, Simsic J, et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 32: 109-120, 2000.
16. Abbate A, Biondi-Zoccai GGL, Baldi A. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol 193: 145-153, 2002.
17. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in endstage heart failure. N Engl J Med 335: 1182-1189, 1996.
18. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 336: 1131-1141, 1997.
19. Saraste A, Pulkki K, Kallajoki M, et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest 29: 380-386, 1999.
20. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355: 1575-1581, 2000.
21. Yu CM, Tipoe GL, Wing-Hon Lai K, Lau CP. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 38: 1207-1215, 2001.
22. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587, 2000.
23. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675, 2001.
24. Tendera M, Ochala A. Overview of the results of recent beta blocker trials. Curr Opin Cardiol 16: 180-185, 2001.
25. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357: 1385-1390, 2001.
26. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 29: 1060-1066, 1997.
27. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105: 868-873, 2002.
28. Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N Engl J Med 346: 5-15, 2002.
29. Laflamme MA, Myerson D, Saffitz; JE, Murry CE. Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts. Circ Res 90: 634-640, 2002.
30. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 410: 701-705, 2001.
31. Stamm C, Westphal B, Kleine HD, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361: 45-46, 2003.
32. Tse HF, Kwong YL, Chan JKF, Lo G, Ho CL, Lau CP. Angiogenesis in ischemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361: 47-49, 2003.